Adaptive Biotechnologies (ADPT) Cost of Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Cost of Revenue across 9 years of filings, most recently posting $20.2 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 12.03% year-over-year to $20.2 million; the TTM figure through Jun 2026 stood at $75.3 million (up 7.98% YoY), while the FY2025 annual figure was $71.4 million, down 1.0% from the prior year.
• Cost of Revenue came in at $20.2 million for Q2 2026 at Adaptive Biotechnologies, up from $18.7 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $20.2 million in Q2 2026 to a low of $13.2 million in Q1 2022.
• Average Cost of Revenue over 5 years is $17.5 million, with a median of $18.0 million recorded in 2024.
• Year-over-year, Cost of Revenue jumped 41.61% in 2023 and decreased 13.85% in 2024.
• Over 5 years, Cost of Revenue stood at $16.6 million in 2022, then grew by 18.25% to $19.6 million in 2023, then declined by 8.01% to $18.0 million in 2024, then gained by 0.99% to $18.2 million in 2025, then advanced by 10.65% to $20.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $20.2 million in Q2 2026, $18.7 million in Q1 2026, and $18.2 million in Q4 2025.